drugset
drugset / Trial / NCT05147272

Study of RP-6306 With Gemcitabine in Advanced Solid Tumors

NCT05147272 ↗

Phase 1 Terminated 67 enrolled Debiopharm International SA Repare Therapeutics · collab
NaSequentialOpen-labelTreatment

Summary

The primary purpose of this study is to assess the safety and tolerability of RP-6306 in combination gemcitabine, in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) of RP-6306 in combination with gemcitabine, identify a recommended phase 2 dose (RP2D) and preferred schedule, examine preliminary pharmacokinetics (PK) and assess anti-tumor activity.

Timeline

Start
2021-12-16
Primary completion
2024-08-28
Completion
2024-08-28

Outcome

Outcome not reported

Stopped: “Sponsor decided to terminate the study”

Drugs

EvaluationDrugModalityDoseRoute
Subject Lunresertib Small molecule — Oral
Background Gemcitabine Small molecule — Intravenous

Indications

No indication recorded.